Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Vital Chemtech
Quarter-by-quarter operating performance
Financials of Vital Chemtech
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| Sales + | 58 | 117 | 98 | 134 | 133 |
| Expenses + | 46 | 102 | 98 | 123 | 121 |
| Operating Profit | 12 | 15 | 0 | 11 | 11 |
| OPM % | 20% | 13% | 0% | 8% | 8% |
| Other Income + | 0 | 0 | 3 | 2 | 1 |
| Interest | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 2 | 3 | 5 | 5 |
| Profit before tax | 11 | 11 | -0 | 6 | 5 |
| Tax % | 26% | 30% | 269% | 35% | |
| Net Profit + | 8 | 8 | -1 | 4 | 3 |
| EPS in Rs | 11.75 | 3.36 | -0.54 | 1.70 | 1.29 |
| Dividend Payout % | 0% | 15% | -92% | 0% |
Financials of Vital Chemtech
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 7 | 24 | 24 | 24 | 24 |
| Reserves | 8 | 66 | 60 | 68 | 69 |
| Borrowings + | 36 | 29 | 26 | 48 | 66 |
| Other Liabilities + | 30 | 19 | 27 | 41 | 33 |
| Total Liabilities | 81 | 138 | 137 | 182 | 193 |
| Fixed Assets + | 17 | 25 | 43 | 68 | 39 |
| CWIP | 0 | 0 | 0 | 15 | 54 |
| Investments | 3 | 15 | 35 | 20 | 14 |
| Other Assets + | 61 | 98 | 60 | 78 | 86 |
| Total Assets | 81 | 138 | 137 | 182 | 193 |
Financials of Vital Chemtech
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -13 | -8 | 14 | 6 |
| Cash from Investing Activity + | 1 | -26 | -35 | -30 |
| Cash from Financing Activity + | 18 | 58 | -9 | 25 |
| Net Cash Flow | 6 | 24 | -30 | 0 |
| Free Cash Flow | -22 | -18 | -7 | -40 |
| CFO/OP | -91% | -36% | 7,410% | 71% |
Financials of Vital Chemtech
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 264 | 120 | 146 | 128 |
| Inventory Days | 87 | 57 | 61 | 47 |
| Days Payable | 265 | 65 | 111 | 121 |
| Cash Conversion Cycle | 87 | 112 | 96 | 54 |
| Working Capital Days | 59 | 116 | 78 | 72 |
| ROCE % | 15% | 0% | 7% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…